Abstract
A new drug-dosage from of Mitomycin C-adsorbed activated carbon particles (MMC-CH) was administered to 50 cancerous patients in terminal stage. This time 26 patients with carcinomatous peritoneal effusion were studied for the effects of MMC-CH.
This MMC-CH therapy was markedly effective in 10 and moderately effective in 2 patients but 14 patients did not respond to the therapy, overall efficacy rate being 46.2%. Eight of 12 patients who well responded to the therapy survived for more than 6 months. An improvement in performance status was noted in 7 (58.2%) patients and they could be discharged from the hospital temporally.
This new type of anti-cancer drug demonstrated high efficacy to stomach cancer with especially scirrhus type.
Adverse effects included fever and abdominal symptoms, and myelosupression, impaired liver and renal functions were observed. All findings were transient.
